Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Slides:

Advertisements

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Advertisements

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

The absence of ADCC by nivolumab in vitro.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

coTCRcys-transduced T cells control tumor growth in vivo.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

CD4+ and CD8+ TILs express surface CD137.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Neutralization of CSF1 and Ad5-HRG treatment.

BTK-activated signaling regulates PDAC tumorigenesis.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

PD-1 expression in ovarian cancer.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Expression of HO-1 by the FAP+/F4/80+ tumoral macrophages.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Comparative effect of anti-TIM3 against experimental tumors.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

In vivo effects of TTFields on intradermal tumors in mice.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PDL192 and inhibit the growth of xenograft tumors.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

Ex vivo profiling of PD-1 blockade using MDOTS

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

PEGPH20 depletes HA and decompresses intratumoral vessels.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. A–D, mice with B16 tumors were treated on days 3, 7, and 10 after tumor implantation with a single antibody or a combination of ch1N11 and anti–PD-1, and tumors were excised on day 12. E–H, K1735 tumors from mice treated weekly with a single antibody or a combination of ch1N11 and anti–PD-1 were excised when tumors reached a size of 800 to 1,000 mm3. Single-cell preparations of B16 or K1735 tumors were stained with antibodies specific to CD45+ (A and E), CD8+ (B and F), CD4+ Teff/Treg ratio (C and G), and CD8 Teff/Treg ratio (D and H). Data are expressed as group mean and individual animals of %CD45/total cells of dissociated tumor, %CD8+/CD45+, %CD4+/Treg (CD4+CD25+FoxP3+), and %CD8+/Treg by FACS analysis. Statistically significant differences between treatment groups were determined by the Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.005; and ****, P < 0.001. Bruce D. Freimark et al. Cancer Immunol Res 2016;4:531-540 ©2016 by American Association for Cancer Research